Elevate your neurological research from initial discovery to diagnostics through consistent measurement of neurofilament light (NfL).

The Quanterix Simoa® NfL assay is a highly sensitive laboratory test crafted to precisely gauge NfL levels in serum, plasma, or cerebrospinal fluid (CSF) samples. Utilizing Quanterix’s Simoa® platform, this neurofilament light chain assay employs digital immunoassay technology to detect and quantify biomarkers at extremely low levels.

The advantages of employing the neurofilament light chain test with the Simoa® NfL Assay are as follows:

  • A highly sensitive and specific measurement of NfL, enabling the accurate and early detection of neurodegenerative diseases in research applications.
  • Compatible with a range of sample types, including blood and CSF, making it a versatile neurofilament light chain assay.

What is Neurofilament Light?

NfL (or Nf-Light) is a 68-kDa cytoskeletal intermediate filament protein found in neurons. NfL binds to the 200 kDa Neurofilament heavy (NfH) and the 125 kDa Neurofilament medium (NfM) to create neurofilaments. They are important elements of the neuronal cytoskeleton and are thought to be mainly involved in controlling axon diameter and offering structural support to the axon.

Neurofilaments are released after axonal injury or neuronal degeneration, sometimes in large amounts. This makes NfL an excellent choice for a biomarker for a variety of neuropathological conditions.

For researchers looking into neurodegenerative diseases such as frontotemporal dementia, multiple sclerosis, traumatic brain injury, and others, NfL assays that can reliably identify NfL in the blood and CSF provide important information.

Applications and intended use

The Quanterix Simoa® NfL assay has undergone validation for its application in both clinical and diagnostic research settings as a neurofilament light chain assay. The antibodies used in the assay demonstrate cross-reactivity with NfL epitopes from murine, bovine, and macaque species, allowing researchers to utilize the assay for studies involving these animals as well as humans.

The Simoa® NfL test is a beneficial instrument for researchers investigating neuropathologies. Researchers can expedite the road from discovery to diagnosis and acquire insights into the role of NfL in the disease process by monitoring NfL protein levels in the blood:

  • Create novel neuro-prognostic and diagnostic tools
  • Determine and evaluate potential medication candidates
  • Verify recently identified biomarkers

Compatible instruments

  • Advantage Plus: HD-X
  • Advantage: HD-1/HD-X/SR-X

Simoa® NF-light™ V2 advantage kit performance


  • Analytical LLOQ: 0.345 pg/mL
  • Functional LLOQ (serum and plasma): 1.38 pg/mL
  • Functional ULOQ (serum and plasma): 1440 pg/mL
  • Functional LLOQ (CSF): 34.5 pg/mL
  • Functional ULOQ (CSF): 36000 pg/mL
  • LOD: 0.085 pg/mL; range 0.026-0.162 pg/mL
  • Tests per kit: 96


  • Analytical LLOQ: 0.640 pg/mL
  • Functional LLOQ (serum and plasma): 2.56 pg/mL
  • Functional ULOQ (serum and plasma): 1440 pg/mL
  • Functional LLOQ (CSF): 64.0 pg/mL
  • Functional ULOQ (CSF): 36000 pg/mL
  • LOD: 0.141 pg/mL; range 0.021-0.814 pg/mL
  • Tests per kit: 96

Kit contents

The assay kit includes all of the reagents and controls needed to run 96 tests, making it easy to use and adaptable to a wide range of sample types.

Other Equipment by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.